BioTuesdays

Achillion gets FDA breakthrough therapy designation for danicopan

Achillion Pharmaceuticals’ (NASDAQ:ACHN) danicopan received FDA breakthrough therapy designation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

In PNH, the complement system destroys red blood cells in both the circulatory – or intravascular system – and extravascular systems such as the liver or spleen, leading to anemia. Complement D factor in particular, is believed to play a role in the destruction of extravascular red blood cells.

The FDA’s decision was based on positive data from an ongoing Phase 2 trial testing the safety and efficacy of danicopan – a factor D inhibitor – in combination with intravenous eculizumab, a complement C5 inhibitor. 

“Danicopan, with its demonstrated ability to limit both intravascular and extravascular hemolysis with oral administration, has the potential to benefit a significant number of patients with PNH that continue to have an unmet medical need on standard of care,” Joseph Truitt, Achillion’s president and CEO, said in a statement. 

Achillion expects to report topline data from the Phase 2 trial by the end of 2019 and plans to advance danicopan into Phase 3 studies in early 2020.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.